As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Zura Bio Limited. The largest reported stake is AI Biotechnology LLC's, at 18.2%. 14 filings are on record since July 16, 2025 (Schedule 13D/A, March 2, 2026).
Sell to companies like Zura Bio Limited? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Great Point Partners, LLC · Percent: 4.44% · SCHEDULE 13G/A
- · Holder: Venrock Healthcare Capital Partners III, L.P. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Suvretta Capital Management, LLC · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Jpmorgan Chase & Co · Percent: 4.7% · SCHEDULE 13G/A
- · Holder: AI Biotechnology LLC · Percent: 18.2% · SCHEDULE 13D/A
Zura Bio Limited has 14 Schedule 13D or 13G filings on record since 2025-07-16. 4 holders' latest filing reports 5% or more of class a ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| AI Biotechnology LLC | 18.2% | 19,699,071 | SCHEDULE 13D/A, 2026-03-02 | 2026-02-26 |
| Athanor Capital | 15.7% | 11,581,402 | SCHEDULE 13D, 2026-01-27 | 2026-01-23 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 9,816,384 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Suvretta Capital Management, LLC | 9.9% | 9,524,263 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
| Jpmorgan Chase & Co | 4.7% | 4,471,316 | SCHEDULE 13G/A, 2026-05-06 | 2026-04-30 |
| Great Point Partners, LLC | 4.44% | 4,215,930 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Deep Track Capital, LP | 0.4% | 259,014 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Zura Bio Limited and the warning signs.
Free to see. No signup.
Keep reading
More on Zura Bio Limited and the records around it.
Zura Bio Limited elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- AI Biotechnology LLC also filed stake reports on 3 other companies: Latigo Biotherapeutics, Inc. (Nov 2026), Yarrow Bioscience, Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
- Suvretta Capital Management, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Zura Bio Limited
Get an email when Zura Bio Limited files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zura Bio Limited?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Zura Bio Limited: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zura Bio Limited covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Athanor Capital
The securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through 4(j) of Schedule 13D. The Reporting Persons may, from time to time, review their investment in the Issuer and may engage in discussions with management or the board of directors of the Issuer regarding the Issuer's business, operations and prospects, subject to applicable law. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or whether to adopt plans or proposals of the type specified above or otherwise.Item 4 of the SCHEDULE 13D filed 2026-01-27
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | Jpmorgan Chase & Co. | 7.5% | SCHEDULE 13G |
| 2025-08-14 | Deep Track Capital, LP | 7.13% | SCHEDULE 13G/A |
| 2025-08-14 | Venrock Healthcare Capital Partners III, L.P. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 0.4% | SCHEDULE 13G/A |
| 2025-11-14 | Great Point Partners, LLC | 5.87% | SCHEDULE 13G/A |
| 2026-01-02 | Athanor Capital | 15.7% | SCHEDULE 13G |
| 2026-01-27 | Athanor Capital | 15.7% | SCHEDULE 13D |
| 2026-02-13 | Suvretta Capital Management, LLC | 8.6% | SCHEDULE 13G/A |
| 2026-02-17 | Great Point Partners, LLC | 5.18% | SCHEDULE 13G/A |
| 2026-03-02 | AI Biotechnology LLC | 18.2% | SCHEDULE 13D/A |
| 2026-05-06 | Jpmorgan Chase & Co | 4.7% | SCHEDULE 13G/A |
| 2026-05-12 | Suvretta Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Great Point Partners, LLC | 4.44% | SCHEDULE 13G/A |
| 2026-05-15 | Venrock Healthcare Capital Partners III, L.P. | 9.9% | SCHEDULE 13G/A |
Questions about who owns Zura Bio Limited
Who owns Zura Bio Limited?
On this page, 4 holders' latest ownership filings report 5% or more of Zura Bio Limited: AI Biotechnology LLC (18.2%, Schedule 13D/A, filed 2026-03-02), Athanor Capital (15.7%, Schedule 13D, filed 2026-01-27), Venrock Healthcare Capital Partners III, L.P. (9.9%, Schedule 13G/A, filed 2026-05-15) and Suvretta Capital Management, LLC (9.9%, Schedule 13G/A, filed 2026-05-12).
Who are the largest shareholders of Zura Bio Limited?
By the share each holder's latest filing reports, the largest holders of Zura Bio Limited on this page are AI Biotechnology LLC (18.2%), Athanor Capital (15.7%) and Venrock Healthcare Capital Partners III, L.P. (9.9%).
When did AI Biotechnology LLC buy into Zura Bio Limited?
The filings give report dates, not purchase dates. The earliest filing from AI Biotechnology LLC on this page is the Schedule 13D/A, filed 2026-03-02, reporting 18.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Zura Bio Limited
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 22, 2026 | Leadership change: Someit Sidhu departs, Director | — | Leadership changes | Source |
| April 23, 2026 | Leadership change: Marlyn Mathew appointed, Vice President, Finance and Accounting | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Zura Bio Limited. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.